European Organisation for Research and Treatment of Cancer - EORTC: Melanoma trials

The registry lists 16 Melanoma studies with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 7Phase 3 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and BinimetinibActive, not recruitingNCT03235245Phase 2
• SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial AccessWithdrawnNCT02507947
• Minimal SN Tumor BurdenActive, not recruitingNCT01942603
• Adjuvant PEG Intron in Ulcerated MelanomaStatus unknownNCT01502696Phase 3
• BI 2536 in Treating Patients With Recurrent or Metastatic Solid TumorsCompletedNCT00526149Phase 2
• Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye MelanomaTerminatedNCT00110123Phase 3
• Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With SurgeryStatus unknownNCT00086866Phase 2
• Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic MelanomaTerminatedNCT00085059Phase 2
• Vaccine Therapy in Treating Patients With Melanoma of the EyeTerminatedNCT00036816Phase 3
• Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the BrainTerminatedNCT00020839Phase 3
• E7070 in Treating Patients With Stage IV MelanomaCompletedNCT00014625Phase 2
• Interferon Alfa Following Surgery in Treating Patients With Stage III MelanomaStatus unknownNCT00006249Phase 3
• Vaccine Therapy in Treating Patients With Primary Stage II MelanomaStatus unknownNCT00005052Phase 3
• ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic MelanomaCompletedNCT00003989Phase 2
• High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III MelanomaStatus unknownNCT00002763Phase 3
• Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00002669Phase 2